Identifying factors contributing to poor outcomes in patients with gastric cancer.

Not Applicable

Completed

• Conditions: Gastric adenocarcinomas; Cancer

• Registration Number: ISRCTN35024819
• Lead Sponsor: Department of Surgery, Onomichi General Hospital

Brief Summary

2020 Results article in https://pubmed.ncbi.nlm.nih.gov/32758144/ (added 24/09/2021)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2017-06-30
• Study Start: 2019-03-26
• Last Update Posted: 4 October 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 182

Inclusion Criteria

Post-curative resection gastric cancer patients

Exclusion Criteria

N/A

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1. Disease-free survival is defined as the time between the date of surgery and disease recurrence or the last available follow-up.<br> 2. Overall survival is defined as the time between the date of surgery and death or the last available follow-up.<br>

Secondary Outcome Measures

Name	Time	Method
<br> 1. Absolute neutrophil and lymphocyte counts are measured using routine blood and biochemical tests on the day before surgery.<br> 2. Serum albumin is measured using routine blood and biochemical tests on the day before surgery.<br> 3. C-reactive protein (CRP) concentrations are measured using routine blood and biochemical tests on the day before surgery.<br> 4. Prognosis is measured using the modified Glasgow Prognosis Score, perineural invasion and neutrophil to lymphocyte ratio on the day before surgery.<br> 5. Diagnosis is determined using surgical pathology reports after surgery.<br>